Navigation Links
When Prescribing New Drugs for Crohn's Disease or Ulcerative Colitis, Surveyed EU5 Gastroenterologists Will Prioritize Remission Rates Over Cost and Reimbursement Hurdles
Date:12/16/2013

BURLINGTON, Mass., Dec. 16, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, when considering the most important attributes for prescribing emerging therapies for Crohn's disease (CD) and ulcerative colitis (UC), instead of using leading anti-TNF agents (Merck's Remicade and AbbVie's Humira), 44 to 70 percent of surveyed gastroenterologists cite higher rates of induction and maintenance of remission as the primary driver. In addition, 12 to 34 percent of surveyed gastroenterologists identify superior efficacy over anti-TNFs in head-to-head trials as another driver, while only up to 10 percent of physicians list the nonclinical factors, lower cost burden and fewer reimbursement restrictions.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

Lack of initial efficacy and waning efficacy over time are also the primary reasons currently driving discontinuation of the anti-TNF-alpha agents, according to survey respondents. While the emerging biologics vedolizumab (Takeda) for CD and UC and Stelara (Janssen) for CD show at least comparable efficacy at maintenance of remission when indirectly compared to Remicade, in the absence of head-to-head comparative data that show superiority over this agent or other anti-TNFs, vedolizumab and Stelarawill face challenges in gaining preferential uptake.

The European Physician & Payer Forum report entitled Crohn's Disease and Ulcerative Colitis in the EU5: How Will Pricing and Reimbursement Decisions for Novel Biologics and Oral Immunomodulators Impact Prescribing? also emphasizes the importance of direct comparative data for favorable pricing and reimbursement of emerging biologics. As more rigorous health technology assessments that focus on added benefit are introduced across the EU5,
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Nations Largest Medical Society Says Doctors Should Check Drug Database Before Prescribing Addictive Drugs, Says Consumer Watchdog Campaign
2. New Study Evaluates Psychotropic Prescribing For Persons with Intellectual Disabilities, Other Psychiatric Disorders
3. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
4. U.S. Physician Prescribing Behavior Impacted by Health Insurance Exchanges and Accountable Care Organizations
5. Lack of Formulary Access Tops List of Limitations Primary Care Physicians Face With e-Prescribing Systems, Says New Research Report from SciMedica Group MR&C
6. Paul Kauffman of Accident Fund to Present on Identifying Risky Opioid Prescribing Patterns at 99th Annual International Association of Industrial Accident Boards & Commissions Conference
7. Differences Over Pathways Developed by Oncologists and MCOs May Create Conflict Over Prescribing Decisions in Early-Line Treatment
8. Abuse-Deterrent Formulations of Purdues OxyContin and Endo Pharmaceuticals Opana ER Have Not Increased PCPs Comfort When Prescribing These Products for Chronic Pain
9. U.S. and European Rheumatologists Agree That a Therapys Induction of Remission is One of the Attributes That Most Influences Their Prescribing Decisions in Rheumatoid Arthritis
10. Approval for One Neuropathic Pain Indication is Sufficient to Support Physician Prescribing and Payer Reimbursement Across Multiple Neuropathic Pain Populations
11. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... the "Electrocardiogram (ECG) Devices - Global Trends, Estimates ... http://photos.prnewswire.com/prnh/20130307/600769 Global ... million by 2016. The North America ... market share while Europe claims ...
(Date:12/15/2014)... , December 15, 2014 BerGenBio ... for aggressive drug resistant cancers, today announces that it ... private placing from new and existing investors. ... support the development of its pipeline of innovative cancer ... its lead drug candidate, BGB324, a first-in-class selective Axl ...
(Date:12/15/2014)... and BRIDGEWATER, N.J. , Dec. 15, ... Sanofi US (EURONEXT: SAN and NYSE: SNY) are collaborating ... launch Cholesterol Counts , an awareness program that ... numbers, and the risks associated with high LDL-C (bad ... CholesterolCounts .com to take a brief poll and ...
Breaking Medicine Technology:Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
... HORSHAM, Pa. , July 28 Teva Respiratory ... efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol ... all efficacy endpoints, demonstrating a statistically significant benefit as compared to ... similar to placebo. , , ...
... BOCA RATON, Fla. , July 28 ... Pharma, the company will market Methylphenidate Solution, the generic ... an Abbreviated New Drug Application (ANDA).  Under the terms ... Tris Pharma, and marketed and distributed by Breckenridge on ...
Cached Medicine Technology:Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 2Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 3Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 4Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 5Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 6Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ) 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... , , When: Wednesday, June 17, 2009, 10:30am Eastern (9:30am Central; 8:30am, ... (toll-free), 1-719-325-4759 (local access), ... Participant passcode: 2895940, Where: Pacific Health Summit, ... Pacific Board Room, ...
... prestigious Hartford Doctoral Fellows and Hartford Faculty ... new grants to eleven researchers in the field of geriatric ... John A. Hartford Foundation and administered by The ... nationwide Geriatric Social Work Initiative (GSWI), which seeks ...
... Targeting children may be an effective use of limited supplies ... Trust and the EU. The study suggests that, used to ... of pandemics such as the current swine flu. As ... flu, countries are looking at measures to control the spread ...
... Mass., June 17 Registration is underway for the CPAP SUCCESS ... Sessions begin on Monday, July 6 at 4PM at 541 ... CPAP SUCCESS GROUP is designed to help struggling CPAP users become ... use CPAP more easily and effectively by learning simple relaxation techniques ...
... and oral human growth hormone formulations provide significant pharmacological responses ... ACCESS PHARMACEUTICALS, INC. (OTC Bulletin ... signed evaluation agreements with two biopharmaceutical companies for its ... terms of the agreements, both companies plan to evaluate Access, ...
... Lower doses safe and effective after heart attack and stroke ... pill rivaroxaban (Xarelto) lowers the risk of stroke, heart attack ... or suffer from unstable angina, a new trial shows. , ... involved in blood clotting. In earlier studies, the drug was ...
Cached Medicine News:Health News:Accelerated Development of New Treatment for Multi Drug-Resistant Tuberculosis: TB Alliance and Tibotec Announce Unique Partnership to Develop TMC207 2Health News:Accelerated Development of New Treatment for Multi Drug-Resistant Tuberculosis: TB Alliance and Tibotec Announce Unique Partnership to Develop TMC207 3Health News:Hartford grants increase support for geriatric social work training 2Health News:Hartford grants increase support for geriatric social work training 3Health News:Vaccinating children may be effective at helping control spread of influenza, experts say 2Health News:Help for Struggling CPAP Users Comes to Sleep HealthCenters in Weymouth 2Health News:Access Pharmaceuticals Announces Initiation of Two New Cobalamin(TM) Oral Insulin Drug Delivery Collaborations 2Health News:Access Pharmaceuticals Announces Initiation of Two New Cobalamin(TM) Oral Insulin Drug Delivery Collaborations 3Health News:New Anticoagulant Pill Works Well in Trial 2Health News:New Anticoagulant Pill Works Well in Trial 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: